Showing results (441-450 of 510) with videos related to

Sort By:
Pageof 51
The Lancet. Neurology|June 14, 2024
Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headacheAnja S Petersen, Nunu Lund, Peter J Goadsby, et al.
Headache|June 3, 2021
Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequencyRyotaro Ishii, Todd J Schwedt, Gina Dumkrieger, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|December 11, 2008
Imaging patients with suspected brain tumour: guidance for primary careDavid P Kernick, Fayyaz Ahmed, Anish Bahra, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Cephalalgia : an International Journal of Headache|February 14, 2020
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatmentDavid W Dodick, Peter J Goadsby, Christian Lucas, et al.
JAMA Neurology|December 20, 2017
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical TrialVladimir Skljarevski, Tina M Oakes, Qi Zhang, et al.
Neurology|April 29, 2021
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY StudyPeter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, et al.
The Lancet. Neurology|April 19, 2025
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trialCristina Tassorelli, Rigmor H Jensen, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|June 15, 2023
Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of casesAlina Buture, Esther M Tomkins, Arif Shukralla, et al.
The Lancet. Neurology|October 10, 2014
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trialDavid W Dodick, Peter J Goadsby, Stephen D Silberstein, et al.
Pageof 51